AHA Coding Clinic® for HCPCS - 2018 Issue 1; For Your Information

New HCPCS codes for the reporting of biosimilar products

Effective April 1, 2018, three new HCPCS codes will be available for the reporting of biosimilar products. Currently biosimilar products are reported with HCPCS code Q5102, Injection, infliximab, biosimilar, 10 mg, which will be discontinued on March 31, 2018. HCPCS code Q5102 will be replaced with HCPCS code Q5103 and Q5104, effective April 1 2018. Also, beginning April 1 2018, modifiers that describe the manufacturer of a biosimilar product (ie, ZA, ZB, and ZC) will no longer be required for Medicare reporting of HCPCS codes for biosimilar products. The new HCPCS codes and their code descriptors are listed in...

To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.

The AHA Coding Clinic for HCPCS includes:

  • The official publication for Level I HCPCS (CPT-4 codes) for hospital providers
  • Also specific Level II HCPCS codes for hospitals, physicians and other health professionals
  • Current newsletters added each quarter
  • Full Archives back to 2001
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information page link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - HCPCS +Archives

free demo
request yours today
for any budget
sign IN
welcome back!